Descemet Endothelial Thickness Comparison Trial (DETECT) II is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 60 patients with Fuchs endothelial dystrophy to DMEK versus Descemet Stripping Only (DSO) with adjunctive Ripasudil.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
60
Stanford University
Palo Alto, California, United States
RECRUITINGUniversity of California Davis
Sacramento, California, United States
RECRUITINGUniversity of Miami
Palm Beach Gardens, Florida, United States
Best spectacle-corrected visual acuity (BSCVA)
Best spectacle-corrected visual acuity (BSCVA)
Time frame: 12 months
Best spectacle-corrected visual acuity (BSCVA)
Best spectacle-corrected visual acuity (BSCVA)
Time frame: 3, 6 and 24 months
Endothelial cell density
Endothelial cell density
Time frame: 3, 6, and 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
RECRUITINGLegacy Devers Eye Institute
Portland, Oregon, United States
RECRUITINGOregon Health & Science University
Portland, Oregon, United States
RECRUITINGUniversity of Pennsylvania
Philadelphia, Pennsylvania, United States
RECRUITINGWills Eye Hospital
Philadelphia, Pennsylvania, United States
RECRUITING